Table 3.
Biochemical markers of bone turnover change after treatment.
| Patient No. | Serum TRACP-5b (mU/dL) |
Serum P1NP (ng/ml) |
||||
|---|---|---|---|---|---|---|
| Pre | 6 months later | 1 year later | Pre | 6 months later | 1 year later | |
| 1 | 641 | 187 | 72 | 74.4 | 49.5 | 23.4 |
| 2 | 394 | – | 159 | 186 | – | 25.5 |
| 3 | 539 | 295 | 173 | 150 | 59.2 | 30.3 |
| 4 | 169 | 147 | 77 | 21.4 | 51.8 | 16.1 |
| 5 | 104 | – | 94 | 28.1 | – | 36.2 |
| Mean ± SD | 369.4 ± 231.2 | 209.7 ± 76.6 | 115.0 ± 47.5 | 92.0 ± 73.4 | 53.5 ± 5.1 | 26.3 ± 7.5 |
| P-value | 0.06 | 0.11 | ||||
*P-value <0.05; statistically significant compared to before administering romosozumab.
SD, standard deviation; TRACP-5b, tartrate-resistant acid phosphatase-5b; P1NP, procollagen type 1 N-terminal propeptide.